Skip to content
AnalystLens

Exelixis 8-K Report, Financial Results (Nov 4, 2025)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed November 4, 2025
Period End
November 4, 2025
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · Jun ’24Jun ’24

Summary

Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Exelixis) reported financial results for the quarter ended September 30, 2025 (the company's fiscal quarter ended October 3, 2025), with total revenues of $597.8 milliona, including net product revenues of $542.9 million from the cabozantinib franchise in the U.S. GAAP net income was $193.6 million, or $0.69 per diluted share, compared with $118.0 million, or $0.40 per diluted share, in the prior-year quarter.

Non-GAAP net income, which excludes stock-based compensation net of tax, was $217.9 millionb, or $0.78 per diluted share. Collaboration revenues declined to $54.8 million from $61.5 million, mainly due to lower milestone-related revenue and development cost reimbursements. Restructuring expenses were $19.8 million, tied to a workforce reorganization and the closure of the King of Prussia, Pennsylvania office, with aggregate charges estimated at approximately $20.5 million.

The company updated its fiscal 2025 guidance, raising total revenues to $2.30 billion to $2.35 billionc (from $2.25 billion to $2.35 billion) and net product revenues to $2.10 billion to $2.15 billion. It also lowered its R&D expense guidance to $850 million to $900 million and its effective tax rate guidance to 17% to 18%. On the pipeline front, Exelixis intends to submit a New Drug Application for zanzalintinib with atezolizumab in previously treated metastatic colorectal cancer in the U.S. by the end of 2025, following STELLAR-303 results that met one dual primary endpoint.

The filing also reports the Board authorized a new stock repurchase program of up to $750 milliond before December 31, 2026. The filing discloses that the company's Board authorized the new repurchase program in October 2025, and that as of September 30, 2025, Exelixis had repurchased $895.3 million of its common stock under prior programs at an average price of $37.18 per share. Investors should weigh the strong product revenue growth and new buyback authorization against the decline in collaboration revenue and the pending regulatory submission for zanzalintinib, which the company noted may be affected by U.S. federal government shutdown limitations on FDA services.

Key Highlights

  1. Total revenues of $597.8 million for the quarter, up from $539.5 million a year earlier; net product revenues of $542.9 million, up from $478.1 million.
  2. GAAP diluted EPS of $0.69 versus $0.40 in the prior-year quarter; non-GAAP diluted EPS of $0.78 versus $0.47.
  3. Collaboration revenues fell to $54.8 million from $61.5 million, primarily on lower milestone revenue and development cost reimbursements, partly offset by higher royalty revenue.
  4. Fiscal 2025 guidance updated: total revenues $2.30 billion to $2.35 billion, net product revenues $2.10 billion to $2.15 billion, R&D expenses $850 million to $900 million, and effective tax rate 17% to 18%.
  5. New stock repurchase program authorized for up to $750 million before December 31, 2026, the fifth such program since March 2023; $895.3 million repurchased under prior programs through September 30, 2025.
  6. Plans to submit a New Drug Application for zanzalintinib with atezolizumab in previously treated metastatic colorectal cancer in the U.S. by year-end 2025, based on STELLAR-303 results.
  7. Restructuring expenses of $19.8 million for the quarter, with aggregate reorganization charges estimated at approximately $20.5 million, including closure of the King of Prussia, Pennsylvania office.

Frequently Asked Questions

  1. How did Exelixis perform in the third quarter of 2025?

    Total revenues were $597.8 million, up from $539.5 million, driven by net product revenues of $542.9 million from CABOMETYX and COMETRIQ in the U.S. GAAP net income was $193.6 million, or $0.69 per diluted share, compared with $0.40 per diluted share a year earlier.

  2. Why did collaboration revenues decline?

    Collaboration revenues were $54.8 million versus $61.5 million, primarily due to lower milestone-related revenues recognized in the quarter and lower development cost reimbursements earned. These were partly offset by higher royalty revenues on cabozantinib sales outside the U.S. generated by partner Ipsen, which totaled $46.3 million in royalties for the quarter.

  3. What changed in the fiscal 2025 guidance?

    Total revenue guidance was narrowed to $2.30 billion to $2.35 billion from $2.25 billion to $2.35 billion, and net product revenue guidance was narrowed to $2.10 billion to $2.15 billion from $2.05 billion to $2.15 billion. R&D expense guidance was lowered to $850 million to $900 million from $925 million to $975 million, and the effective tax rate guidance was reduced to 17% to 18% from 21% to 23%.

  4. What is the new stock repurchase program?

    The Board authorized the repurchase of up to $750 million of common stock before December 31, 2026. Repurchases may be made through open market purchases, block trades, Rule 10b5-1 plans, accelerated share repurchases, exchange transactions, or combinations thereof, and the programs may be modified, suspended or discontinued at any time.

  5. What is the status of zanzalintinib's regulatory path?

    Based on STELLAR-303, which met one of its dual primary endpoints with a statistically significant overall survival benefit in the intention-to-treat population, Exelixis intends to submit a New Drug Application in the U.S. for zanzalintinib with atezolizumab in previously treated metastatic colorectal cancer by the end of 2025. The company noted this submission is subject to limitations on FDA services due to the ongoing U.S. federal government shutdown.